Pfizer stock: Blackstone backs berobenatide with new funding deal
Published on 11/12/2026 at 16:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFunding supports obesity pipeline
- Blackstone will fund up to 1.5 billion US dollars of berobenatide development costs through 2028.
- Pfizer retains operational control while Blackstone's payments depend on regulatory and commercial milestones.
- The program includes 10 ongoing or planned Phase 3 trials for the investigational monthly GLP-1 candidate.
Pfizer announced on Wednesday, November 11, that Blackstone Life Sciences will help fund development of berobenatide, an investigational monthly GLP-1 receptor agonist for obesity and related conditions. The agreement gives Pfizer additional support for a late-stage program while leaving operational control with the drugmaker.
The announcement was published by Pfizer Investor Relations. Blackstone-managed funds will cover development costs through 2028. In return, Blackstone may receive milestone-based payments if the monthly injectable treatment wins US regulatory approval as a monotherapy and reaches specified commercial sales milestones.
Funding shifts obesity spending
Pfizer said the program includes 10 ongoing and planned Phase 3 trials for berobenatide, also known as PF'3944. The candidate is being studied for chronic weight management and obesity-related conditions including knee osteoarthritis and obstructive sleep apnea. Pfizer also plans more than 20 obesity and related-comorbidity trials in 2026.
Blackstone will not receive ownership or development rights to berobenatide. Pfizer retains full operational control and decision-making authority, while any earned milestone payments would be made over several years. The structure can reduce Pfizer's near-term development burden, but the economic benefit remains dependent on clinical progress, regulatory approval and future sales.
Stock remains below morning level
Pfizer stock traded at 26.37 euros on Lang & Schwarz at 16:42 CET on Thursday, November 12, 2026, 0.38 percent above the Xetra close of Wednesday, November 11.
The quote stood at 26.66 euros in the latest relevant own report at 08:33 CET on November 12 and was 26.37 euros at 16:42 CET, a decline of 1.09 percent. That intraday comparison is distinct from the Xetra-session comparison above.
Pfizer Inc. stock facts
- Company: Pfizer Inc.
- ISIN: US7170811035
- Ticker: PFE
- Lang & Schwarz quote: 26.37 euros at 16:42 CET on November 12, 2026
- Xetra close: 26.27 euros on November 11, 2026
US equities remain the broader market backdrop for Pfizer investors; see the S&P 500.
More news and analyses on Pfizer stock.
